Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL28752565 | 1.00 | CNR2 (0.54) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL7294141 | 0.94 | POLB (0.56) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL5567744 | 0.94 | POLB (0.56) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL6439569 | 0.94 | POLB (0.56) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL7300117 | 0.79 | HDAC2 (0.51) | CNR2MEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL3024846 | 0.79 | POLB (0.59) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL3024849 | 0.79 | POLB (0.59) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL19099236 | 0.75 | POLB (0.63) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL14701618 | 0.75 | POLB (0.63) | CNR2POLBCNR1MEN1CYP1A2 | |
| SCHEMBL7674546 | 0.74 | POLB (0.67) | CNR2POLBCNR1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183443-B2 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2007-02-27 | — | — | US | disclosed |
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | ADH1C, ADH1A, ADH5 | CNR2 4217/4885POLB 225/4885CNR1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.